Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90739 · Verify on the e-Formulary ↗ (DIN 02422727)
Source record
DIN 02422727: Mint-Olopatadine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 523600094; group id 635; item number 1606; lccId None; manufacturer id MIN
Source form: Oph Sol-5mL Pk; strength: 0.1%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $26.1300; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02422727
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90739Interchangeable products
Apo-Olopatadine · DIN 02305054 · not recorded
Co Olopatadine 0.1% · DIN 02403986 · not recorded
Jamp-Olopatadine · DIN 02458411 · not recorded
Olopatadine · DIN 02521172 · not recorded
Patanol · DIN 02233143 · not recorded
Sandoz Olopatadine · DIN 02358913 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02422727
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Olopatadine · DIN 02521172 · 0.1% · Oph Sol-5mL Pk
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Olopatadine · DIN 02521172
Manufacturer: Sanis Health Inc.; listing date 2022-05-31
Health Canada: Marketed since 2022-07-13 · brand OLOPATADINE · ATC S01GX09 OLOPATADINE · form Solution · route Ophthalmic · ingredients OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1 %/W/V · company Sanis health inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101039 · Verify on the e-Formulary ↗ (DIN 02521172)
Source record
DIN 02521172: Olopatadine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 523600094; group id 635; item number 1606; lccId None; manufacturer id SAI
Source form: Oph Sol-5mL Pk; strength: 0.1%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $26.1300; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02521172
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101039Interchangeable products
Apo-Olopatadine · DIN 02305054 · not recorded
Co Olopatadine 0.1% · DIN 02403986 · not recorded
Jamp-Olopatadine · DIN 02458411 · not recorded
Mint-Olopatadine · DIN 02422727 · not recorded
Patanol · DIN 02233143 · not recorded
Sandoz Olopatadine · DIN 02358913 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02521172
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Patanol · DIN 02233143 · 0.1% · Oph Sol-5mL Pk
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Patanol · DIN 02233143
Manufacturer: Novartis Pharma Canada Inc.; listing date 2013-01-29
Health Canada: Marketed since 2018-06-13 · brand PATANOL · ATC S01GX09 OLOPATADINE · form Solution · route Ophthalmic · ingredients OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Patanol: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=53275 · Verify on the e-Formulary ↗ (DIN 02233143)
Source record
DIN 02233143: Patanol
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 523600094; group id 635; item number 1606; lccId None; manufacturer id NOV
Source form: Oph Sol-5mL Pk; strength: 0.1%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02233143
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=53275Interchangeable products
Apo-Olopatadine · DIN 02305054 · not recorded
Co Olopatadine 0.1% · DIN 02403986 · not recorded
Jamp-Olopatadine · DIN 02458411 · not recorded
Mint-Olopatadine · DIN 02422727 · not recorded
Olopatadine · DIN 02521172 · not recorded
Sandoz Olopatadine · DIN 02358913 · not recorded
Shortage status: resolved shortage (ended 2018-06-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02233143
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84395 · Verify on the e-Formulary ↗ (DIN 02358913)
Source record
DIN 02358913: Sandoz Olopatadine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 523600094; group id 635; item number 1606; lccId None; manufacturer id SDZ
Source form: Oph Sol-5mL Pk; strength: 0.1%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $26.1300; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02358913
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84395Interchangeable products
Apo-Olopatadine · DIN 02305054 · not recorded
Co Olopatadine 0.1% · DIN 02403986 · not recorded
Jamp-Olopatadine · DIN 02458411 · not recorded
Mint-Olopatadine · DIN 02422727 · not recorded
Olopatadine · DIN 02521172 · not recorded
Patanol · DIN 02233143 · not recorded
Shortage status: resolved shortage (ended 2021-12-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02358913
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99796 · Verify on the e-Formulary ↗ (DIN 02508605)
Source record
DIN 02508605: Mint-Olopatadine 0.2%
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 523600137; group id 635; item number 1605; lccId None; manufacturer id MIN
Source form: Oph Sol-2.5mL Pk; strength: 0.2%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $26.1300; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02508605
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99796Interchangeable products
Act Olopatadine 0.2% · DIN 02404095 · not recorded
Apo-Olopatadine · DIN 02402823 · not recorded
Jamp Olopatadine 0.2% · DIN 02560976 · not recorded
Olopatadine 0.2% · DIN 02541653 · not recorded
Pataday · DIN 02362171 · not recorded
Sandoz Olopatadine 0.2% · DIN 02420171 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02508605
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103030 · Verify on the e-Formulary ↗ (DIN 02541653)
Source record
DIN 02541653: Olopatadine 0.2%
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 523600137; group id 635; item number 1605; lccId None; manufacturer id SAI
Source form: Oph Sol-2.5mL Pk; strength: 0.2%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $26.1300; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02541653
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103030Interchangeable products
Act Olopatadine 0.2% · DIN 02404095 · not recorded
Apo-Olopatadine · DIN 02402823 · not recorded
Jamp Olopatadine 0.2% · DIN 02560976 · not recorded
Mint-Olopatadine 0.2% · DIN 02508605 · not recorded
Pataday · DIN 02362171 · not recorded
Sandoz Olopatadine 0.2% · DIN 02420171 · not recorded
Shortage status: resolved shortage (ended 2025-12-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02541653
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Pataday · DIN 02362171 · 0.2% · Oph Sol-2.5mL Pk
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pataday · DIN 02362171
Manufacturer: Novartis Pharma Canada Inc.; listing date 2014-05-29
Health Canada: Marketed since 2018-05-09 · brand PATADAY · ATC S01GX09 OLOPATADINE · form Solution · route Ophthalmic · ingredients OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.2 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Pataday: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84721 · Verify on the e-Formulary ↗ (DIN 02362171)
Source record
DIN 02362171: Pataday
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 523600137; group id 635; item number 1605; lccId None; manufacturer id NOV
Source form: Oph Sol-2.5mL Pk; strength: 0.2%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02362171
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84721Interchangeable products
Act Olopatadine 0.2% · DIN 02404095 · not recorded
Apo-Olopatadine · DIN 02402823 · not recorded
Jamp Olopatadine 0.2% · DIN 02560976 · not recorded
Mint-Olopatadine 0.2% · DIN 02508605 · not recorded
Olopatadine 0.2% · DIN 02541653 · not recorded
Sandoz Olopatadine 0.2% · DIN 02420171 · not recorded
Shortage status: resolved shortage (ended 2025-10-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02362171
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90478 · Verify on the e-Formulary ↗ (DIN 02420171)
Source record
DIN 02420171: Sandoz Olopatadine 0.2%
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 523600137; group id 635; item number 1605; lccId None; manufacturer id SDZ
Source form: Oph Sol-2.5mL Pk; strength: 0.2%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $26.1300; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02420171
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90478Interchangeable products
Act Olopatadine 0.2% · DIN 02404095 · not recorded
Apo-Olopatadine · DIN 02402823 · not recorded
Jamp Olopatadine 0.2% · DIN 02560976 · not recorded
Mint-Olopatadine 0.2% · DIN 02508605 · not recorded
Olopatadine 0.2% · DIN 02541653 · not recorded
Pataday · DIN 02362171 · not recorded
Shortage status: resolved shortage (ended 2026-08-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02420171
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Olopatadine · DIN 02305054 · 0.1% · Oph Sol-5mL Pk
Off-Formulary Interchangeable, not an ODB benefitDormant since 2020-08-04 · checked 2026-09-02 · What does dormant mean?
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Olopatadine · DIN 02305054
Manufacturer: Apotex Inc.; listing date 2013-01-29
Health Canada: Dormant since 2020-08-04 · brand APO-OLOPATADINE · ATC S01GX09 OLOPATADINE · form Solution · route Ophthalmic · ingredients OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1 % · company Apotex inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79042 · Verify on the e-Formulary ↗ (DIN 02305054)
Source record
DIN 02305054: Apo-Olopatadine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 523600094; group id 635; item number 1606; lccId None; manufacturer id APX
Source form: Oph Sol-5mL Pk; strength: 0.1%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $26.1300; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02305054
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79042Interchangeable products
Co Olopatadine 0.1% · DIN 02403986 · not recorded
Jamp-Olopatadine · DIN 02458411 · not recorded
Mint-Olopatadine · DIN 02422727 · not recorded
Olopatadine · DIN 02521172 · not recorded
Patanol · DIN 02233143 · not recorded
Sandoz Olopatadine · DIN 02358913 · not recorded
Shortage status: active shortage (reported 2020-06-01, last updated 2020-06-04) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02305054
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2020-08-04 — choose a marketed DIN from the same-category list.
Jamp-Olopatadine · DIN 02458411 · 0.1% · Oph Sol-5mL Pk
Off-Formulary Interchangeable, not an ODB benefitDormant since 2025-07-31 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Olopatadine · DIN 02458411
Manufacturer: Jamp Pharma Corporation; listing date 2017-03-28
Health Canada: Dormant since 2025-07-31 · brand JAMP-OLOPATADINE · ATC S01GX09 OLOPATADINE · form Solution · route Ophthalmic · ingredients OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1 %/W/V · company Jamp pharma corporation · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94555 · Verify on the e-Formulary ↗ (DIN 02458411)
Source record
DIN 02458411: Jamp-Olopatadine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 523600094; group id 635; item number 1606; lccId None; manufacturer id JPC
Source form: Oph Sol-5mL Pk; strength: 0.1%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $26.1300; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02458411
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94555Interchangeable products
Apo-Olopatadine · DIN 02305054 · not recorded
Co Olopatadine 0.1% · DIN 02403986 · not recorded
Mint-Olopatadine · DIN 02422727 · not recorded
Olopatadine · DIN 02521172 · not recorded
Patanol · DIN 02233143 · not recorded
Sandoz Olopatadine · DIN 02358913 · not recorded
Shortage status: active shortage (reported 2025-08-07, estimated to end 2026-03-31, last updated 2025-09-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02458411
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-07-31 — choose a marketed DIN from the same-category list.
Apo-Olopatadine · DIN 02402823 · 0.2% · Oph Sol-2.5mL Pk
Off-Formulary Interchangeable, not an ODB benefitDormant since 2025-04-03 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Olopatadine · DIN 02402823
Manufacturer: Apotex Inc.; listing date 2014-05-29
Health Canada: Dormant since 2025-04-03 · brand APO-OLOPATADINE · ATC S01GX09 OLOPATADINE · form Solution · route Ophthalmic · ingredients OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.2 %/W/V · company Apotex inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88766 · Verify on the e-Formulary ↗ (DIN 02402823)
Source record
DIN 02402823: Apo-Olopatadine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 523600137; group id 635; item number 1605; lccId None; manufacturer id APX
Source form: Oph Sol-2.5mL Pk; strength: 0.2%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $26.1300; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02402823
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88766Interchangeable products
Act Olopatadine 0.2% · DIN 02404095 · not recorded
Jamp Olopatadine 0.2% · DIN 02560976 · not recorded
Mint-Olopatadine 0.2% · DIN 02508605 · not recorded
Olopatadine 0.2% · DIN 02541653 · not recorded
Pataday · DIN 02362171 · not recorded
Sandoz Olopatadine 0.2% · DIN 02420171 · not recorded
Shortage status: active shortage (reported 2024-03-26, last updated 2024-03-27) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02402823
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-04-03 — choose a marketed DIN from the same-category list.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106398 · Verify on the e-Formulary ↗ (DIN 02560976)
Source record
DIN 02560976: Jamp Olopatadine 0.2%
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 523600137; group id 635; item number 1605; lccId None; manufacturer id JPC
Source form: Oph Sol-2.5mL Pk; strength: 0.2%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $26.1300; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02560976
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106398Interchangeable products
Act Olopatadine 0.2% · DIN 02404095 · not recorded
Apo-Olopatadine · DIN 02402823 · not recorded
Mint-Olopatadine 0.2% · DIN 02508605 · not recorded
Olopatadine 0.2% · DIN 02541653 · not recorded
Pataday · DIN 02362171 · not recorded
Sandoz Olopatadine 0.2% · DIN 02420171 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02560976
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Approved since 2025-09-10 — choose a marketed DIN from the same-category list.
Co Olopatadine 0.1% · DIN 02403986 · 0.1% · Oph Sol-5mL Pk
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.Discontinued 2021-07-30 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Co Olopatadine 0.1% · DIN 02403986
Manufacturer: Cobalt Pharmaceuticals Company; listing date 2014-02-27
Health Canada: Cancelled post market since 2021-07-30 · brand ACT OLOPATADINE 0.1% · ATC S01GX09 OLOPATADINE · form Solution · route Ophthalmic · ingredients OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1 %/W/V · company Teva canada limited · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88874 · Verify on the e-Formulary ↗ (DIN 02403986)
Source record
DIN 02403986: Co Olopatadine 0.1%
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 523600094; group id 635; item number 1606; lccId None; manufacturer id COB
Source form: Oph Sol-5mL Pk; strength: 0.1%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $26.1300; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02403986
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88874Interchangeable products
Apo-Olopatadine · DIN 02305054 · not recorded
Jamp-Olopatadine · DIN 02458411 · not recorded
Mint-Olopatadine · DIN 02422727 · not recorded
Olopatadine · DIN 02521172 · not recorded
Patanol · DIN 02233143 · not recorded
Sandoz Olopatadine · DIN 02358913 · not recorded
Shortage status: active shortage (reported 2018-09-01, last updated 2018-10-23) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02403986
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.Discontinued 2021-07-30 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Act Olopatadine 0.2% · DIN 02404095
Manufacturer: Actavis Pharma Company; listing date 2014-05-29
Health Canada: Cancelled post market since 2021-07-30 · brand ACT OLOPATADINE 0.2% · ATC S01GX09 OLOPATADINE · form Solution · route Ophthalmic · ingredients OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.2 %/W/V · company Teva canada limited · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88887 · Verify on the e-Formulary ↗ (DIN 02404095)
Source record
DIN 02404095: Act Olopatadine 0.2%
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 523600137; group id 635; item number 1605; lccId None; manufacturer id ACV
Source form: Oph Sol-2.5mL Pk; strength: 0.2%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $26.1300; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02404095
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88887Interchangeable products
Apo-Olopatadine · DIN 02402823 · not recorded
Jamp Olopatadine 0.2% · DIN 02560976 · not recorded
Mint-Olopatadine 0.2% · DIN 02508605 · not recorded
Olopatadine 0.2% · DIN 02541653 · not recorded
Pataday · DIN 02362171 · not recorded
Sandoz Olopatadine 0.2% · DIN 02420171 · not recorded
Shortage status: active shortage (reported 2018-09-01, last updated 2018-10-23) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02404095
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered
Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL
Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE
52:36 Other Eye, Ear, Nose and Throat Agents
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
No displayed matched alternative is a general benefit.
KETOTIFEN · Off-Formulary Interchangeable, not an ODB benefit
• treatment of allergic conjunctivitis.
PM: https://pdf.hres.ca/dpd_pm/00076212.PDF; date February 23, 2012; DIN 02242324; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE
PATANOL® (olopatadine hydrochloride ophthalmic solution) is indicated for the treatment of
allergic conjunctivitis.
Geriatrics: No overall difference in safety has been observed between elderly and other adult
patients.
Pediatrics (3 – 16 years of age): PATANOL administered three times a day for six weeks was
shown to be safe and well-tolerated in subjects who were ages 3 years and older.
https://pdf.hres.ca/dpd_pm/00044108.PDF
PM date: March 2, 2018
Source product: PATANOL; DIN 02233143; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Apo-Olopatadine · DIN 02305054
Shortage status: active shortage (reported 2020-06-01, last updated 2020-06-04) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02305054
Jamp-Olopatadine · DIN 02458411
Shortage status: active shortage (reported 2025-08-07, estimated to end 2026-03-31, last updated 2025-09-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02458411
Apo-Olopatadine · DIN 02402823
Shortage status: active shortage (reported 2024-03-26, last updated 2024-03-27) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02402823
Co Olopatadine 0.1% · DIN 02403986
Shortage status: active shortage (reported 2018-09-01, last updated 2018-10-23) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02403986
Act Olopatadine 0.2% · DIN 02404095
Shortage status: active shortage (reported 2018-09-01, last updated 2018-10-23) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02404095
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)
Other review policies
For Mint-Olopatadine, Olopatadine, Patanol, Sandoz Olopatadine, Mint-Olopatadine 0.2%, Olopatadine 0.2%, Pataday, Sandoz Olopatadine 0.2%, Apo-Olopatadine, Jamp-Olopatadine, Jamp Olopatadine 0.2%, Co Olopatadine 0.1%, Act Olopatadine 0.2%: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.